The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors.

Brunner, Philippe; Jörg, Ann-Catherine; Glatz, Katharina; Bubendorf, Lukas; Radojewski, Piotr; Umlauft, Maria; Marincek, Nicolas; Spanjol, Petar Marko; Krause, Thomas Michael; Dumont, Rebecca A; Maecke, Helmut R; Müller-Brand, Jan; Briel, Matthias; Schmitt, Anja; Perren, Aurel; Walter, Martin Alexander (2017). The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors. European journal of nuclear medicine and molecular imaging, 44(3), pp. 468-475. Springer 10.1007/s00259-016-3486-2

[img] Text
art%3A10.1007%2Fs00259-016-3486-2.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy
[img]
Preview
Text
EJNM-D-16-00297 - Revised Manuscript - The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (7MB) | Preview

PURPOSE Our aim was to assess the prognostic and predictive value of somatostatin receptor 2 (sstr2) in neuroendocrine tumors (NETs). METHODS We established a tissue microarray and imaging database from NET patients that received sstr2-targeted radiopeptide therapy with yttrium-90-DOTATOC, lutetium-177-DOTATOC or alternative treatment. We used univariate and multivariate analyses to identify prognostic and predictive markers for overall survival, including sstr2-imaging and sstr2-immunohistochemistry. RESULTS We included a total of 279 patients. In these patients, sstr2-immunohistochemistry was an independent prognostic marker for overall survival (HR: 0.82, 95 % CI: 0.67 - 0.99, n = 279, p = 0.037). In DOTATOC patients, sstr2-expression on immunohistochemistry correlated with tumor uptake on sstr2-imaging (n = 170, p < 0.001); however, sstr2-imaging showed a higher prognostic accuracy (positive predictive value: +27 %, 95 % CI: 3 - 56 %, p = 0.025). Sstr2-expression did not predict a benefit of DOTATOC over alternative treatment (p = 0.93). CONCLUSIONS Our results suggest sstr2 as an independent prognostic marker in NETs. Sstr2-immunohistochemistry correlates with sstr2-imaging; however, sstr2-imaging is more accurate for determining the individual prognosis.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Service Sector > Institute of Pathology
04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Forschungsbereich Pavillon 52 > Forschungsgruppe Klinische Radiopharmazie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Forschungsbereich Pavillon 52 > Forschungsgruppe Klinische Radiopharmazie

UniBE Contributor:

Radojewski, Piotr; Spanjol, Petar Marko; Krause, Thomas Michael; Schmitt Kurrer, Anja; Perren, Aurel and Walter, Martin Alexander

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health

ISSN:

1619-7070

Publisher:

Springer

Language:

English

Submitter:

Franziska Nicoletti

Date Deposited:

01 Feb 2017 12:28

Last Modified:

01 Apr 2018 02:30

Publisher DOI:

10.1007/s00259-016-3486-2

PubMed ID:

27539020

Uncontrolled Keywords:

Individualized therapy; Metabolic therapy; PRRT; Tailored therapy; Targeted therapy

BORIS DOI:

10.7892/boris.94326

URI:

https://boris.unibe.ch/id/eprint/94326

Actions (login required)

Edit item Edit item
Provide Feedback